Why the study?
Current LDL-C lowering therapies do not or minimally lower Lp(a), highlighting the need to review the clinical importance and therapeutic consequences of Lp(a) measurement.
Should Lp(a) be routinely measured to identify patients at high risk for ASCVD who may benefit from aggressive risk factor modification and emerging Lp(a)-lowering therapies?
Should Lp(a) be routinely measured to identify patients at high risk for ASCVD who may benefit from aggressive risk factor modification and emerging Lp(a)-lowering therapies?
Lp(a) should be measured at least once in every patient to identify those with very high levels who may benefit from aggressive risk factor modification and future Lp(a)-lowering therapies.
Answers are grounded in this paper and cite their sources.
Once-lifetime Lp(a) testing now flags patients for intensified LDL-C control; leaves open event reduction from RNA therapies pending phase 3.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Nurmohamed et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: